Biocryst Pharmaceuticals (BCRX) Net Income (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Net Income came in at -$721.8 million in Q1 2026, down 2255762.5% YoY from N/an in Q1 2025, and down 393.6% on a QoQ basis from $245.8 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Net Income (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Net Income data on file, last reported at -$721.8 million in Q1 2026.
- Quarterly Net Income fell 2255762.5% year-over-year to -$721.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$458.0 million (down 756.52% YoY) and the FY2025 annual result came in at $263.9 million, up 396.87% from the prior year.
- Net Income fell to -$721.8 million in Q1 2026, from $245.8 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $245.8 million in Q4 2025 to a low of -$721.8 million in Q1 2026.
- A 5-year average of -$60.0 million and a median of -$36.1 million in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2025 — Net Income surged 1017.5% — and 2026, when it tumbled 2255762.5%.
- Tracing BCRX's Net Income over 5 years: stood at -$71.5 million in 2022, then increased by 13.71% to -$61.7 million in 2023, then surged by 56.59% to -$26.8 million in 2024, then surged by 1017.5% to $245.8 million in 2025, then tumbled by 393.6% to -$721.8 million in 2026.
- The last three Net Income figures came in at -$721.8 million (Q1 2026), $245.8 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -69.36 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.43 Bn | 2.08 Bn | 214.41 Mn | 78.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.40 Mn |
| Mar 31, 2026 | -721.81 Mn |
| Dec 31, 2025 | 245.85 Mn |
| Sep 30, 2025 | 12.90 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | -26.80 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -35.38 Mn |
| Dec 31, 2023 | -61.73 Mn |
| Sep 30, 2023 | -36.15 Mn |
| Jun 30, 2023 | -75.33 Mn |
| Mar 31, 2023 | -53.33 Mn |
| Dec 31, 2022 | -71.54 Mn |
| Sep 30, 2022 | -42.52 Mn |
| Jun 30, 2022 | -58.86 Mn |
| Mar 31, 2022 | -74.20 Mn |
| Dec 31, 2021 | -17.78 Mn |
| Sep 30, 2021 | -58.80 Mn |